Dec 21, 2019
Complete Response Letter Issued from U.S. FDA for Investigational Long-Acting HIV Regimen
Aug 22, 2019
Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months
Jul 30, 2019
Five Years on, 3.9 Million People in the Developing World Have Access to HIV Treatment Dolutegravir, Thanks to Access-oriented Voluntary Licensing Agreements
Mar 07, 2019
Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy
Feb 05, 2019
3D Communications Expands its Executive Communications and Value Communications Programs with Hiring of Former Industry Executive
Nov 15, 2018
Global HIV Diagnostics and Therapeutics Markets Report 2018-2023 Featuring Abbott Laboratories, Bio-Rad Laboratories, Cipla, GSK, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific
Jul 20, 2018
Global HIV Drugs Market 2018-2023: Key Players are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
Jun 25, 2018
bioMONTR Labs Announces Laboratory Service Agreement With ViiV Healthcare
May 02, 2018
The Medicines Patent Pool Adds New Suppliers from South Africa and South Korea to its Growing Generic Manufacturing Network
Dec 19, 2017
$179.9 Billion Enzyme Inhibitors Markets, 2022
Nov 21, 2017
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
Aug 03, 2017
Shionogi Inc. President and CEO John Keller to Receive Innovation Award from NY American Chemical Society CME Group
Jul 25, 2017
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
Jun 01, 2017
Janssen Announces Submissions in Europe and US for Single-Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment